Periodic Reporting for period 1 - FasNaGel (NOVEL THERAPEUTIC NANOHYDROGEL FOR ACUTE AND CHRONIC PAIN TREATMENT TARGETED TO THE NERVES FASCIA)
Período documentado: 2018-06-01 hasta 2018-11-30
Development of a technical and economic feasibility study of FasNaGel. It will also contain a detailed business plan with the envisaged exploitation means for the further commercialisation of the product, marketing and communication strategies, analysis of the regulatory standards.
DESCRIPTION OF WORK
Commercial feasibility assessment will be carried out in order to analyse the best commercial strategy in every market: analysing the market, and existing solutions, customers, competitors as well as the overall economic, political, cultural and technical environment. i+Med will contact relevant stakeholders (such as hospitals, health insurance companies, public agencies) and survey potential customers, analyse their preferences and assess their willingness to buy FasNaGel. In case it is not possible to reach the agreement with the players targeted, other companies operating in the same market segment will be contacted. Furthermore, the inclusion of FasNaGel in other markets will be analysed.
A financial feasibility assessment based on the commercial exploitation of FasNaGel in five different scenarios has been proposed:
1. i+Med is the only manufacturer and distributor of the product
2. i+Med manufactures the product and i+Med and a partner distribute the product: the brand is licenced to a partner who also can distribute and sell FasNaGel
3. i+Med licenses for the manufacturing, sales and distribution of the product to a third party
4. i+Med manufactures FasNaGel and sells its product via a worldwide distributor network.
5. i+Med sells the whole project
It has
After reviewing the different scenarios, i+Med has concluded that the scenarios that most adapt to the reality and the business strategy of I + Med would be the licensing of FasNaGel for the manufacturing, sales and distribution of the product to a third party.
A market study has been carried out
A Detailed analysis of the regulatory standards to be met by the new medicinal product, has been identified
A Risk analysis and Contingency plan to study the main bottlenecks and possible solutions for the commercialisation of the product have been identified .
A feasibility report including a five-year Business and Exploitation Plan has been done